Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 1/20 | 0.46 |
| ▸ | JAK1 | P23458 | 1/20 | 0.46 |
| ▸ | JAK3 | P52333 | 1/20 | 0.46 |
| ▸ | PIK3CA | P42336 | 13/20 | 0.43 |
| ▸ | MAPK8 | P45983 | 12/20 | 0.43 |
| ▸ | MAPK9 | P45984 | 12/20 | 0.43 |
| ▸ | MAPK10 | P53779 | 12/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 12/20 | 0.43 |
| ▸ | NPC1 | O15118 | 4/20 | 0.41 |
| ▸ | RAB9A | P51151 | 4/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.40 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.40 |
| ▸ | RELA | Q04206 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12979639 | 0.96 | PIK3CA (0.45) | JAK2JAK1JAK3PIK3CAMAPK8 | |
| SCHEMBL12979024 | 0.88 | ALDH1A1 (0.48) | PIK3CAMAPK8MAPK9MAPK10MAPK1 | |
| SCHEMBL5441526 | 0.84 | JAK2 (0.55) | JAK2JAK1JAK3PIK3CAMAPK8 | |
| SCHEMBL12979358 | 0.83 | MAPK1 (0.45) | PIK3CAMAPK8MAPK9MAPK10MAPK1 | |
| SCHEMBL5449743 | 0.83 | MAPK1 (0.61) | JAK2JAK1JAK3PIK3CAMAPK8 | |
| SCHEMBL13192005 | 0.83 | MAPK1 (0.46) | JAK2JAK1JAK3PIK3CAMAPK8 | |
| SCHEMBL12979737 | 0.83 | PIK3CA (0.49) | PIK3CAMAPK8MAPK9MAPK10MAPK1 | |
| SCHEMBL5451753 | 0.81 | MAPK1 (0.61) | JAK2JAK1JAK3PIK3CAMAPK8 | |
| SCHEMBL12979515 | 0.80 | PIK3CA (0.52) | JAK2JAK1JAK3PIK3CAMAPK8 | |
| SCHEMBL12978902 | 0.80 | PIK3CA (0.66) | PIK3CAMAPK8MAPK9MAPK10MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120259151-A1 | PYRIDOPYRAZINE DERIVATIVES AND THEIR USE | AETERNA ZENTARIS GMBH (DE) | 2012-10-11 | — | — | US | claimed |
| US-8912189-B2 | Pyridopyrazine derivatives and their use | AETERNA ZENTARIS GMBH (DE) | 2014-12-16 | — | — | US | disclosed |
| US-8912189-B2 | Pyridopyrazine derivatives and their use | AETERNA ZENTARIS GMBH (DE) | 2014-12-16 | — | — | US | disclosed |
| US-8912189-B2 | Pyridopyrazine derivatives and their use | AETERNA ZENTARIS GMBH (DE) | 2014-12-16 | — | — | US | disclosed |
| EP-2694068-A1 | PYRIDOPYRAZINE DERIVATIVES AND THEIR USE | Æterna Zentaris GmbH (DE) | 2014-02-12 | — | — | EP | disclosed |
| WO-2012136694-A1 | PYRIDOPYRAZINE DERIVATIVES AND THEIR USE | ÆTERNA ZENTARIS GMBH (DE) | 2012-10-11 | — | — | WO | disclosed |
| US-20120259151-A1 | PYRIDOPYRAZINE DERIVATIVES AND THEIR USE | AETERNA ZENTARIS GMBH (DE) | 2012-10-11 | — | — | US | disclosed |
| WO-2012136694-A1 | PYRIDOPYRAZINE DERIVATIVES AND THEIR USE | ÆTERNA ZENTARIS GMBH (DE) | 2012-10-11 | — | — | WO | disclosed |
| US-20120259151-A1 | PYRIDOPYRAZINE DERIVATIVES AND THEIR USE | AETERNA ZENTARIS GMBH (DE) | 2012-10-11 | — | — | US | disclosed |
| US-20120259151-A1 | PYRIDOPYRAZINE DERIVATIVES AND THEIR USE | AETERNA ZENTARIS GMBH (DE) | 2012-10-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120259151-A1 | PYRIDOPYRAZINE DERIVATIVES AND THEIR USE | PLPBP, PDXK, MAP4K2 | JAK2 620/4885JAK1 1191/4885JAK3 1092/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.